Azitra, Inc. (NYSEAMERICAN:AZTR) Sees Large Decrease in Short Interest

by · The Cerbat Gem

Azitra, Inc. (NYSEAMERICAN:AZTR – Get Free Report) was the recipient of a large decrease in short interest in the month of May. As of May 15th, there was short interest totaling 126,538 shares, a decrease of 68.2% from the April 30th total of 397,818 shares. Approximately 0.8% of the company’s stock are sold short. Based on an average trading volume of 471,811 shares, the days-to-cover ratio is presently 0.3 days.

Azitra Trading Up 12.0%

Shares of NYSEAMERICAN AZTR traded up $0.02 during trading on Friday, reaching $0.23. 1,357,101 shares of the stock were exchanged, compared to its average volume of 474,277. The business’s 50-day moving average price is $0.23 and its 200 day moving average price is $0.26. Azitra has a twelve month low of $0.10 and a twelve month high of $2.40.

Azitra (NYSEAMERICAN:AZTR – Get Free Report) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.24). Equities research analysts predict that Azitra will post -0.25 EPS for the current fiscal year.

Azitra Company Profile

(Get Free Report)

Azitra Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance.

See Also